BIO CEO McMurry-Heath Steps Down Amid Reported Conflict with Board

Dr. Michelle McMurry-Heath headshot
BIO CEO Dr. Michelle McMurry-Heath has stepped down amid reports of ongoing dissension within the group over its direction.

Biotechnology Innovation Organization (BIO) on Monday announced the resignation of its CEO, molecular immunologist Dr. Michelle McMurry-Heath, after confirming over the weekend that she was on a leave of absence. BIO is the trade association and top lobbying group for

Read More »

Hospital Group Urges MedPAC to Drop Part B Pay-Cut Proposal, Cites 340B Impact

MedPAC chart of drugs add-on amounts
The AHA wants MedPAC to drop a Medicare Part B drug reimbursement policy option it is considering making to Congress on the grounds that it will hurt 340B hospitals.

The American Hospital Association is urging the Medicare Payment Advisory Commission to abandon a Medicare Part B drug reimbursement policy option it is considering making to Congress, arguing that the proposed change would hurt 340B hospitals’ ability to provide care

Read More »

PhRMA Makes its Case for Invalidating Arkansas’s First-of-its-Kind 340B Contract Pharmacy Law

PhRMA wordmark repeated on blue background
"There is no room for states, pharmacies, or other interests to step in and try to supplant” the federal government’s exclusive control over the 340B program, PhRMA told a federal district court in Arkansas late last week.

The 340B program “has always been uniquely federal in nature” and “there is no room for states, pharmacies, or other interests to step in and try to supplant” the federal government’s exclusive control over it, the brand drug industry said

Read More »

Amgen Announces Second Round of Refunds this Year for 340B Overcharges

Amgen wordmark on building facade
Drugmaker Amgen last week extended its existing 340B contract pharmacy restrictions to federal grantees.

Biotech company Amgen said last week it would pay refunds for 340B overcharges occurring in the third and fourth quarters of 2019.

The posting on the U.S. Health Resources and Services Administration website marks Amgen’s second 340B refund notice so far

Read More »

340B Pharmacy Services Company Avita Expands into Clinician and Support Staff Services

Michael Yount, Avita headshot
Maintaining regular access to providers is a challenge for many 340B grantee entities and can make it hard for them to leverage the 340B program, Avita CEO Michael Yount says.

Avita, a leading provider of 340B contract pharmacy and third-party administration services geared toward HIV and LGBTQ+ communities, is expanding into medical practice staffing and management.

Avita announced Oct. 5 that it has acquired HIV/AIDS, LGBTQ+, and primary care health

Read More »

Federal Court Clears Way for Medicare to Boost 340B Hospitals’ Part B Drug Payments

U.S. District Court Washington D.C. building
A federal district court in Washington, D.C., cleared the way for CMS to resume paying hospitals at ASP +6% for 340B drugs in as quickly as two weeks.

A federal district judge on Monday cleared the way for the Centers for Medicare and Medicaid Services (CMS) in as quickly as two weeks to resume paying hospitals at the rate of average sales price (ASP) plus 6% for their

Read More »

340B Report Holding Oct. 28 Webinar on What the Midterm Elections Mean for 340B

Vote Here sign in English, Spanish and Chinese on Election Day
340B Report is holding a webinar Oct. 28 about 340B’s future after the November midterm elections.

Five Washington insiders steeped in knowledge about the 340B program will take part in a 340B Report webinar Oct. 28 about 340B’s future after the November midterm elections.

The event from 1:00 to 2:15 p.m. Eastern is an exclusive free

Read More »

CBO Raises Changing 340B Patient Definition to Ease Pressure on Commercial Insurers

Congressional Budget Office report title page
Changing the 340B patient definition “might reduce hospitals’ and physicians’ incentives to consolidate,” the CBO says in a new analysis.

Changing the 340B patient definition “might reduce hospitals’ and physicians’ incentives to consolidate,” but to what extent “remains highly uncertain,” the Congressional Budget Office says in a new policy analysis.

House Budget Committee Chair John Yarmuth (D-Ky.) asked CBO to

Read More »

Genentech CEO Cites New York Times’ Front Page Story in Appeal for 340B Reforms

Alexander Hardy headshot
Genentech CEO Alexander Hardy cited a recent New York Times investigative article about 340B in an appeal to healthcare leaders to reform the 340B program together.

Genentech CEO Alexander Hardy on Tuesday urged healthcare leaders to reform the 340B program together in the wake of the recent New York Times exposé about a Virginia health system’s alleged misuse of the 340B program.

“As leaders in healthcare,

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report